Beta Bionics, Inc. $BBNX Position Raised by Eversept Partners LP

Eversept Partners LP grew its position in shares of Beta Bionics, Inc. (NASDAQ:BBNX) by 108.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,414,838 shares of the company’s stock after acquiring an additional 736,576 shares during the quarter. Beta Bionics comprises about 0.7% of Eversept Partners LP’s investment portfolio, making the stock its 29th largest holding. Eversept Partners LP’s holdings in Beta Bionics were worth $14,177,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Charles Schwab Investment Management Inc. increased its holdings in shares of Beta Bionics by 0.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 331,623 shares of the company’s stock worth $10,105,000 after acquiring an additional 931 shares during the period. Deutsche Bank AG lifted its position in Beta Bionics by 3.4% in the 4th quarter. Deutsche Bank AG now owns 39,300 shares of the company’s stock valued at $1,197,000 after purchasing an additional 1,296 shares during the last quarter. Summit Securities Group LLC acquired a new position in Beta Bionics during the 4th quarter valued at about $52,000. Caitong International Asset Management Co. Ltd boosted its stake in Beta Bionics by 1,075.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock valued at $61,000 after purchasing an additional 1,818 shares during the period. Finally, Verition Fund Management LLC grew its position in Beta Bionics by 4.0% in the 3rd quarter. Verition Fund Management LLC now owns 47,299 shares of the company’s stock worth $940,000 after purchasing an additional 1,823 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on BBNX shares. Weiss Ratings restated a “sell (e+)” rating on shares of Beta Bionics in a research note on Friday, July 17th. The Goldman Sachs Group boosted their price objective on Beta Bionics from $17.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Leerink Partners decreased their price objective on Beta Bionics from $25.00 to $24.00 and set an “outperform” rating for the company in a report on Wednesday, April 22nd. Truist Financial raised their target price on Beta Bionics from $18.00 to $22.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Finally, Bank of America cut their target price on Beta Bionics from $23.00 to $11.00 and set a “neutral” rating on the stock in a research note on Monday, May 18th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $20.30.

Beta Bionics Stock Up 0.9%

Shares of BBNX opened at $15.99 on Tuesday. The firm has a 50-day moving average price of $14.67 and a 200 day moving average price of $13.49. The firm has a market capitalization of $712.55 million, a PE ratio of -10.59 and a beta of 3.04. Beta Bionics, Inc. has a 52-week low of $8.80 and a 52-week high of $32.71.

Insider Activity at Beta Bionics

In other news, insider Mike Mensinger sold 4,378 shares of the stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $12.61, for a total value of $55,206.58. Following the completion of the transaction, the insider directly owned 184,415 shares in the company, valued at $2,325,473.15. This trade represents a 2.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Stephen Feider sold 4,896 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $17.03, for a total transaction of $83,378.88. Following the transaction, the chief financial officer owned 165,931 shares in the company, valued at $2,825,804.93. This represents a 2.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 40,351 shares of company stock worth $553,961 in the last three months. Insiders own 5.30% of the company’s stock.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.